

# New Venturetec

## NET ASSET VALUE - April 30, 2018

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	<u>500'000</u>	Price: CHF 33.00 (ex.rate 1.47)	<u>USD 11'250'000</u>
	<b>5,000,000</b>		<b>USD 118'500'000</b>

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75'124'350.98
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	6'993'824.57
Unrealized loss	USD	<u>-178'925.76</u>
<b>Total appreciation</b>	<b>USD</b>	<b>6'814'898.81</b>

### NAV

Cost of investments	USD	28'769'158.69
Appreciation of investments	USD	<u>6'814'898.81</u>
Estimated value of investments	USD	<b>35'584'057.50</b>
Convertible Notes	USD	-13'406'005.79
Loan	USD	-7'777'104.91
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	0.00
Cash at bank	USD	<u>931'960.47</u>
<b>Estimated value</b>	<b>USD</b>	<b>15'332'907.27</b>
<b>NAV per share USD</b>		<b>3.07</b>
<b>NAV per share CHF</b>		<b>3.03</b>

Exchange rate USD/CHF	0.9896
<b>Closing Market Price April 30, 2018</b>	<b>CHF 3.74</b>

## New Venturetec NAV - April 30, 2018

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	82.7	4'103'301 Common Shares	5.80	7.50	6'993'824.57	30'774'757.50	84.2
2. Myriad Genetics	4'988'225.76	17.3	170'000 Shares	29.34	28.29	-178'925.76	4'809'300.00	13.2
<b>TOTAL</b>	<b>28'769'158.69</b>	<b>100.0</b>				<b>6'814'898.81</b>	<b>35'584'057.50</b>	<b>97.4</b>